BioNTech’s Crucial Deadline: Investor Focus Shifts to CureVac Takeover Threshold

This week represents a pivotal moment for BioNTech SE, with events set to unfold that could fundamentally shape the biotech firm’s long-term trajectory in oncology. As markets watch with apprehension, a strategic countdown is nearing its conclusion. The seamless acquisition of mRNA rival CureVac hangs in the balance, with the potential to either solidify BioNTech’s path or prolong a period of investor uncertainty.

The tender offer for CureVac is approaching its critical phase. While the official deadline for the share exchange extends into the morning of Wednesday, December 3, 2025, the practical cutoff for most shareholders is Tuesday, December 2, 2025. To meet operational settlement requirements, shares typically must Read more...